Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, December 03, 2020 1:00 - 5:00 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Tracy Klein, PhD, FNP; Caryn Mickelson, PharmD; William Origer, MD; Mark Helm, MD, MBA, FAAP; James Slater, PharmD; Russell Huffman, DNP, PMHNP; Jim Rickards, MD, MBA; Cathy Zehrung RPh; Patrick DeMartino, MD; Stacy Ramirez, PharmD

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; Trevor Douglass, DC, MPH; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Dee Weston, JD; Brandon Wells

Audience: Shirley Quach*, Novartis Pharma; Amy Burns, AllCare; Andrea Willcuts, Takeda; Bill McDougal, Biogen; Bruce Wallace, Azurity; Camille Kerr, Regeneron; Chi Kohlhoff, Viela Bio; Deron Grothe, Teva Pharmaceuticals; George Kitchens, Artia Solutions; Jeff Mussack, Braeburn; Jennifer Shear, Teva Pharmaceuticals; Jenny Tofenhagen, Genentech; Katie Scheelar, Moda; Steve Hall*, Genentech; Kelly Wright; Lori McDermott, Supernus; Maggi Olmon, Abbvie; Mark Kantor, AllCare Health; Matt Bradley, Novartis; Matt Worthy, OHSU; Timothy McFerron, Alkermes; Michael Foster, BMS; Mike Findlien, Otsuka Pharma; Paul Thompson, Alkermes; Rachel Hartman, IHN; Rick Frees, Vertex; Rosalynde Finch, Biogen; Roy Linfield, Sunovion; Suzanne Gauen, Providence; Tina Hartmann, Jazz Pharma; Rebecca Persinger*, Horizon Therapeutics; Patrick Moby; Judy Bachman*; Paul Bachman*

(*) Provided verbal testimony

Written testimony: Posted to OSU Website
I. CALL TO ORDER

   A. The meeting was called to order at approximately 1:06 pm. Introductions were made by Committee members and staff  
   B. Conflict of Interest Declaration - No new conflicts of interest were declared  
   C. Approval of October 2020 minutes presented by Mr. Citron  
      **ACTION: Motion to approve, 2\textsuperscript{nd}, all in favor**  
   D. Department Update provided by Trevor Douglass

II. CONSENT AGENDA TOPICS

   A. Quarterly Utilization Reports  
   B. CMS Annual Report  
   C. P&T Annual Report  
   D. Oncology Policy Update  
   E. Drug Class Literature Scans  
      a. Substance Use Disorder, Opioid and Alcohol  
      b. Newer Antiemetics  
      **Recommendations:**  
      - No PDL changes recommended based on the clinical evidence  
      - Evaluate costs in executive session  
      **ACTION: Motion to approve, 2\textsuperscript{nd}, all in favor**

III. DUR ACTIVITIES

   A. ProDUR Report: Rich Holsapple, RPh  
   B. RetroDUR Report: Dave Engen, PharmD  
   C. Oregon State Drug Review: Kathy Sentena, PharmD  
      - Optimizing use of NPH Insulin in Patient with Type 2 Diabetes Mellitus  
      - Shifts in the Treatment of Community Acquired Pneumonia

IV. DUR OLD BUSINESS

   A. **Asthma/COPD Drug Class Prior Authorization Update:** Kathy Sentena, PharmD  
      **Recommendation:**  
      - Modify ICS/LABA/LAMA PA criteria with updated indication for Trelegy Ellipta  
      **ACTION: Motion to approve, 2\textsuperscript{nd}, all in favor**
B. **Inflammatory Skin Conditions Update**: Deanna Moretz PharmD

**Recommendation:**
- Revise criteria for biologic therapies, dupilumab, atopic dermatitis and topical antipsoriatics to include the assessment of severe disease using validation scoring tool (i.e. DLQI, CDLQI) per HERC guidance

**Public Comments:** Shirley Quach, Novartis

**ACTION:** Motion to approve, 2nd, all in favor

---

V. **PREFERRED DRUG LIST NEW BUSINESS**

A. **Sedative Class Update**: Andrew Gibler, PharmD

**Recommendations:**
- Recommend OHA cover melatonin and make preferred on the PDL
- Update clinical prior authorization criteria
- Evaluate costs in executive session

**ACTION:** The Committee recommended to not require prior authorization for 18 years of age and under

**Motion to approve, 2nd, all in favor**

B. **Teprotumumab New Drug Evaluation**: Sara Fletcher, PharmD

**Recommendations:**
- Designate teprotumumab as non-preferred on the PDL
- Implement proposed clinical PA

**Public Comment:** Rebecca Persinger, Horizon Therapeutics; Judy Bachman & Paul Bachman

**ACTION:** Motion to approve, 2nd, all in favor

C. **Gout Agents Class Update**: Kathy Sentena, PharmD

**Recommendation:**
- No changes to PDL base on clinical evidence
- Update PA criteria to allow colchicine in patient with pericarditis and Behçet’s Syndrome
- Evaluate costs in executive session

**ACTION:** The Committee recommended allowing a small quantity without PA

**Motion to approve, 2nd, all in favor**

D. **Risdiplam New Drug Evaluation**: Dave Engen, PharmD

**Recommendation:**
- Add risdiplam to PDL and designate as non-preferred
- Implement proposed PA criteria

**ACTION:** The Committee recommended adding a request for baseline pulmonary function and a follow up question in the renewal criteria

**Motion to approve, 2nd, all in favor**

**E. Cenegermin New Drug Evaluation:** Megan Herink, PharmD

**Recommendation:**
- Designate Cenegermin as non-preferred on the PDL
- Implement proposed PA criteria

**ACTION:** Motion to approve, 2nd, all in favor

---

**VI. DUR NEW BUSINESS**

**A. Drug Discontinuation Safety Net Policy Proposal:** Sarah Servid, PharmD

**Recommendation:**
- Implement a case management referral program for patients with gaps in care for high risk maintenance medications

**ACTON:** Motion to approve, 2nd, all in favor

**B. Consultation for Antipsychotic in Children Policy Evaluation:** Sarah Servid, PharmD

**Recommendation:**
- Continue to monitor drug therapy changes after referral and consultation for pediatric patients on long-term antipsychotics

**ACTON:** Motion to approve, 2nd, all in favor

---

**VII. EXECUTIVE SESSION**

**Members Present:** Tracy Klein, PhD, FNP; William Origer, MD; Mark Helm, MD, MBA, FAAP; James Slater, PharmD; Russell Huffman, DNP, PMHNP; Cathy Zehrung RPh; Patrick DeMartino, MD; Stacy Ramirez, PharmD

**Staff Present:** Jennifer Bowen, Admin; Roger Citron, RPh; Trevor Douglass, DC, MPH; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Dee Weston, JD; Brandon Wells
VIII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Substance Use Disorder:
   **Recommendation:** No changes to the PDL are recommended

B. Newer Antiemetics:
   **Recommendation:** No changes to the PDL are recommended

C. Sedatives:
   **Recommendation:** Make melatonin tablets and similarly priced generic products preferred pending OHA state plan amendment

D. Gout:
   **Recommendation:** Make Colcrys preferred on the PDL

E. CGRP Inhibitors:
   **Recommendation:** Make Ajovy preferred on PDL

**ACTION:** Motion to approve, 2nd, all in favor

IX. ADJOURN